Therapeutic patents for the treatment of pre-eclampsia

Abstract

Pre-eclampsia (PE) is a pregnancy-specific syndrome that is a principal cause of maternal morbidity and mortality, accounting for almost 15% of pregnancy-associated deaths. In its mild form, PE most commonly presents with the features of maternal hypertension and proteinuria but can swiftly and unpredictably become severe with many extensive and life-threatening complications. The diverse symptoms of PE have made it a difficult disease not only to define, but also to identify a causative agent for the symptoms. It has therefore proved difficult to develop specific drugs that can be used to manage the condition. This review examines the patent literature to reveal current findings that exhibit the potential to target the effects of PE with the aim of either preventing or altering the course of this life-threatening disease of pregnancy.

• angiotensin
• anti-inflammatory
• calcitonin gene-related peptide
• digoxin
• endothelin (ET)
• hypertension
• magnesium
• neurokinin B
• nitric oxide
• pre-eclampsia (PE)
• pregnancy
• prostaglandins
• trophoblast
• vascular endothelial growth factor